Legato Capital Management LLC Purchases 5,506 Shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Legato Capital Management LLC boosted its position in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 26.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 26,720 shares of the company’s stock after purchasing an additional 5,506 shares during the period. Legato Capital Management LLC’s holdings in Harmony Biosciences were worth $919,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. grew its holdings in Harmony Biosciences by 21.2% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,056 shares of the company’s stock valued at $80,000 after purchasing an additional 360 shares during the last quarter. GAMMA Investing LLC grew its holdings in Harmony Biosciences by 92.6% during the 4th quarter. GAMMA Investing LLC now owns 907 shares of the company’s stock valued at $31,000 after purchasing an additional 436 shares during the last quarter. CWM LLC grew its holdings in Harmony Biosciences by 111.7% during the 3rd quarter. CWM LLC now owns 1,469 shares of the company’s stock valued at $59,000 after purchasing an additional 775 shares during the last quarter. KBC Group NV grew its holdings in Harmony Biosciences by 79.9% during the 4th quarter. KBC Group NV now owns 1,844 shares of the company’s stock valued at $63,000 after purchasing an additional 819 shares during the last quarter. Finally, Hedeker Wealth LLC grew its holdings in Harmony Biosciences by 1.2% during the 4th quarter. Hedeker Wealth LLC now owns 76,203 shares of the company’s stock valued at $2,622,000 after purchasing an additional 916 shares during the last quarter. 86.23% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Harmony Biosciences

In other news, insider Jeffrey Dierks sold 10,507 shares of Harmony Biosciences stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $37.01, for a total transaction of $388,864.07. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Jeffrey M. Dayno sold 19,293 shares of Harmony Biosciences stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $40.13, for a total transaction of $774,228.09. The disclosure for this sale can be found here. Insiders sold a total of 72,452 shares of company stock worth $2,831,679 over the last three months. Corporate insiders own 30.80% of the company’s stock.

Harmony Biosciences Price Performance

Shares of HRMY opened at $39.08 on Friday. The company has a market cap of $2.23 billion, a price-to-earnings ratio of 18.52, a price-to-earnings-growth ratio of 0.51 and a beta of 0.80. Harmony Biosciences Holdings, Inc. has a twelve month low of $28.14 and a twelve month high of $41.61. The company has a quick ratio of 3.20, a current ratio of 3.24 and a debt-to-equity ratio of 0.28. The company has a 50 day moving average of $35.95 and a two-hundred day moving average of $35.58.

Analyst Upgrades and Downgrades

HRMY has been the topic of several analyst reports. HC Wainwright reiterated a “buy” rating and set a $75.00 price target on shares of Harmony Biosciences in a report on Monday, January 27th. Cantor Fitzgerald upped their target price on shares of Harmony Biosciences from $51.00 to $58.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 30th. Oppenheimer restated an “outperform” rating and issued a $59.00 target price (up from $56.00) on shares of Harmony Biosciences in a research note on Wednesday, October 30th. Deutsche Bank Aktiengesellschaft began coverage on shares of Harmony Biosciences in a research note on Tuesday. They issued a “buy” rating and a $55.00 target price on the stock. Finally, Needham & Company LLC restated a “buy” rating and issued a $52.00 target price on shares of Harmony Biosciences in a research note on Monday, January 13th. Nine research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Harmony Biosciences currently has an average rating of “Buy” and an average target price of $55.00.

Harmony Biosciences Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.